CLDX vs. NTLA, MYGN, RIOT, NEOG, VIVO, EXAS, RGEN, EXEL, HALO, and IONS
Should you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Riot Platforms (RIOT), Neogen (NEOG), Meridian Bioscience (VIVO), Exact Sciences (EXAS), Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS).
Celldex Therapeutics (NASDAQ:CLDX) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
In the previous week, Intellia Therapeutics had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 7 mentions for Intellia Therapeutics and 5 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.29 beat Intellia Therapeutics' score of 1.02 indicating that Celldex Therapeutics is being referred to more favorably in the media.
Intellia Therapeutics has a net margin of -893.34% compared to Celldex Therapeutics' net margin of -2,385.57%. Celldex Therapeutics' return on equity of -29.55% beat Intellia Therapeutics' return on equity.
Celldex Therapeutics currently has a consensus target price of $66.00, indicating a potential upside of 98.20%. Intellia Therapeutics has a consensus target price of $66.77, indicating a potential upside of 212.30%. Given Intellia Therapeutics' higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than Celldex Therapeutics.
Celldex Therapeutics received 181 more outperform votes than Intellia Therapeutics when rated by MarketBeat users. Likewise, 74.91% of users gave Celldex Therapeutics an outperform vote while only 69.37% of users gave Intellia Therapeutics an outperform vote.
Celldex Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Celldex Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.
88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.8% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Celldex Therapeutics beats Intellia Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Celldex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celldex Therapeutics Competitors List
Related Companies and Tools
